Niagen Bioscience, Inc Stock Price, News & Analysis

Niagen Bioscience (NASDAQ:NAGE) reported third-quarter 2025 results with net sales up 33% to $34.0M and Tru Niagen sales $26.0M (+44%). Net income was $4.6M ($0.06/share) versus $1.9M a year ago, and Adjusted EBITDA rose 120% to $6.4M. Cash from operations for the nine months was $12.8M, with quarter-end cash of $64.3M. The company reaffirmed and raised full-year 2025 net sales guidance to +25%–30% YoY. Operational highlights include the launch of the AboutNAD digital platform, a favorable National Advertising Division decision, and expansion of Niagen Plus distribution to >1,000 clinics. Updated expense outlooks include higher G&A ($8.0–$9.0M).

Niagen Bioscience (NASDAQ: NAGE) will report third quarter 2025 financial results for the period ended September 30, 2025, after market close on Tuesday, November 4, 2025. Management will host an investor conference call on Tuesday, November 4, 2025 at 4:30 p.m. ET to discuss the results and provide a general business update.

Call participants should dial in at least 10 minutes early. Toll-free dial-in: +1 888 596 4144 with Conference ID 8584242. A live webcast will be available on the company investor relations site and a replay will be available from 7:30 p.m. ET on November 4, 2025 through 11:59 p.m. ET on November 11, 2025 (toll-free replay +1 800 770 2030, Replay ID 8584242).

Niagen Bioscience (NASDAQ: NAGE) has expanded the availability of its pharmaceutical-grade Niagen Plus™ products to over 900 clinics nationwide, including more than 50 iCRYO locations. The company's Niagen IV and injections, which boost NAD+ levels, demonstrated superior performance compared to traditional NAD+ IV therapy in clinical studies, featuring 75% shorter infusion times and a 20% increase in whole blood NAD+ levels.

The partnership with iCRYO aligns with both companies' focus on preventative health solutions and longevity. Niagen's nicotinamide riboside (NR) is clinically validated as the most efficient NAD+ booster, addressing the natural decline of NAD+ levels associated with aging and stress. The treatment supports cellular function, metabolic health, and overall well-being.

Niagen Bioscience (NASDAQ: NAGE) has launched an enhanced version of AboutNAD®, a comprehensive online platform dedicated to NAD+ science and research. The website serves as a centralized educational resource focusing on nicotinamide riboside (NR), featuring peer-reviewed studies and scientific advancements in NAD+ biology.

The platform includes a categorized research database, advanced search functionality, expert perspectives, and scientific newsletters. Content is structured around three core principles: evidence-based research, accessibility, and community orientation, aiming to bridge the gap between scientific research and public understanding of NAD+ biology and its role in healthy aging.

Niagen Bioscience (NASDAQ:NAGE) reported strong Q2 2025 financial results, with total net sales increasing 37% to $31.1 million. The company's flagship product Tru Niagen® achieved sales of $22.7 million, growing 22%, while Niagen® ingredient sales surged 135% to $7.4 million. The company reported net income of $3.6 million ($0.05 per share) and improved gross margin by 480 basis points to 65.0%.

Key operational highlights include completing patient dosing in the Phase III NOPARK trial for Parkinson's disease, securing an exclusive license agreement with Haukeland University Hospital, and expanding Niagen Plus products to over 800 wellness clinics. The company raised its full-year 2025 revenue growth outlook to 22-27% from the previous 20-25%.

Niagen Bioscience (NASDAQ: NAGE) has published groundbreaking clinical study results in Aging Cell, demonstrating the efficacy of their patented nicotinamide riboside (NR) ingredient, Niagen®, in treating Werner syndrome (WS), a rare genetic aging disorder. The 52-week randomized, double-blind, placebo-controlled crossover trial showed that daily 1,000mg Niagen supplementation increased NAD+ levels by approximately 140% and improved cardiovascular and skin health markers.

Key findings include improved arterial stiffness, beneficial changes in HDL particles, and reduced skin ulcer size. The study involved nine individuals with WS, with no moderate or severe adverse events reported. This research expands Niagen's rare disease portfolio, which includes promising results in Ataxia Telangiectasia (AT), where the FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation.

Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, announced its participation in Canaccord Genuity's 45th Annual Growth Conference from August 12-14, 2024, in Boston.

CEO Rob Fried and CFO Ozan Pamir will participate in a fireside chat on August 12 at 12:00 PM ET. The executives will also conduct one-on-one meetings with institutional investors during the conference. The presentation will be available via webcast, with a replay accessible on the company's investor relations website.

Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025.

The company will release its Q2 2025 financial results after market close, followed by an investor conference call at 4:30 p.m. ET. Management will discuss the financial performance and provide a business update during the call, which will be accessible via webcast through the company's investor relations website.